Acyl-protein thioesterase 1 (APT1) is considered to be a key enzyme of S-depalmitoylation. Recently, Kathayat et al. [1] revealed the existence of APT1 in mitochondria, which was previously supposed to locate at cytosol and Golgi apparatus [2] . Moreover, APT1 mediates the occurrence of mitochondrial S-depalmitoylation. Kathayat et al.
Acyl-protein thioesterase 1 (APT1) is considered to be a key enzyme of S-depalmitoylation. Recently, Kathayat et al. [1] revealed the existence of APT1 in mitochondria, which was previously supposed to locate at cytosol and Golgi apparatus [2] . Moreover, APT1 mediates the occurrence of mitochondrial S-depalmitoylation. Kathayat et al. [1] adopted a special kind of mitochondrial-targeted S-depalmitoylation fluorescent probe, i.e. mitoDPPs, which could successfully detect APT1 in the mitochondria of live cells. So, the role of APT1 in regulating S-depalmitoylation status in mitochondria broadens a new biological ramification. In fact, there are a multitude of palmitoylated proteins found in mitochondria, which also play regulatory roles in the biological functions of mitochondria [2, 3] . Together, they revealed that abnormal mitochondrial lipid homeostasis is resulted from the alterations in mitochondrial S-palmitoylation activity and that mitoDPPs can be used as a novel tool to test APTs activity in mitochondria.
S-palmitoylation is an important lipid post-translational modification (PTM) of proteins. S-palmitoylation refers that the palmitoyl chain (a 16-carbon fatty acid) is attached to an intracellular cysteine residue through a thioester linkage. The process is facilitated by an enzymatic family of Asp-His-His-Cys (DHHC)-containing transmembrane protein acyltransferases (DHHC-PATs). Most of them exist in the endoplasmic reticulum, Golgi compartment and plasma membrane [4] . S-palmitoylation is responsible for regulating hydrophobicity and altering cellular localization of target proteins. Unlike most lipid PTMs, S-palmitoylation is a dynamically reversible process, which can be readily reversed by cysteine deacylase (Fig. 1) . Depalmitoylation mainly deconjugates palmitate from target substrates, which is the reverse process of palmitoylation. Depalmitoylation is performed by cysteine deacylase 'eraser' enzymes, including palmitoyl-protein thioesterase 1 (PPT1) and acyl-protein thioesterases (APT1 and APT2) [5] . These enzymes are lysosomal and cytosolic proteins. Therefore, previous studies about the targets of S-palmitoylation are mainly focused on cytosolic and transmembrane proteins. However, the expressions of some palmitoylated proteins in mitochondria provide evidence to support the existence of palmitoylation and depalmitoylation in the mitochondria.
Furthermore, it has been revealed that palmitoylation plays an important role in the function of mitochondria via related signaling pathways (Fig. 2) . Some important mitochondrial enzymes, such as glutamate dehydrogenase (GLD) and carbamoyl-phosphate synthetase 1 (CPS 1) are significantly inhibited by palmitoyl-CoA which is the acyl donor for palmitoylation [6] . Notably, the impaired mitochondrial function as well as lipid abnormalities are resulted from ZDHHC13 deficiency, a member of the palmitoyl transferase (PAT) family for catalyzing protein S-palmitoylation [2] . Furthermore, ZDHHC13-deficient mice exhibit lower status of S-palmitoylation in drp1, disrupted mitochondrial dynamics and metabolism. These results indicate the interaction between ZDHHC13 and Drp1 protein [3] . In addition, immunity-related GTPases (IRG) also localizes in the mitochondria. The residual palmitoylation of IRG induces the process of mitochondrial fission [7] . This observation provides a direct link between mitochondrial fission-fusion and S-palmitoylation.
It has also been demonstrated that S-palmitoylation plays a potential role in contributing to various diseases including neurodegenerative disorder, arrhythmia generation and tumorigenesis. Frohlich et al. [8] showed that S-palmitoylation of BCL-2-associated X (BAX) at Cys126 has an effect on connecting mitochondrial outer membrane (MOM) to BAX, which induces BAX-mediated apoptosis. Consequently, aberrant PAT expression decreases BAX S-palmitoylation and inhibits apoptosis, further accelerating malignant tumor cell growth. Interestingly, aggregation of extensive palmitoylated cysteine-string protein α (CSPα) mutants is regarded as a driving force for neurodegenerative disorders [9] . Kim et al. [10] found that the deficiency of PPT1, a cysteine deacylase of depalmitoylation, impairs the recycling of palmitoylated synaptic vesicles (SVs) proteins and contributes to abnormal neurotransmission. Palmitoylation also modulates Ca 2+ permeability induced by AMPA receptor and neuron degeneration, which could be reversed by depalmitoylation [11] . Furthermore, palmitoylation enhances the availability of cardiac voltage-gated sodium channels (Nav1.5) and upregulates cardiac excitability. Their alterations have a profound impact on arrhythmia generation [12] . It has been revealed that palmitoylated synaptonemal complex protein 1 (SCP1) at its NH2 terminus is involved in suppressing angiogenesis and tumorigenesis [13] . Altogether, these findings demonstrated the contributions of palmitoylation in diverse pathological processes. As previously shown, there are unrecognized mitochondrial depalmitoylases, although some depalmitoylated proteins are observed in the mitochondria. Then how does mitochondrial depalmitoylation take place? This crucial question is explicitly answered in a recent report, since the signal from mitoDPPs confirms that not only mitoDPPs localize to mitochondria, but also the activity of S-depalmitoylases in mitochondria is partially ascribed to APT1 [1] . In fact, the development of mitoDPPs is based on a series of evolution in depalmitoylation probes (DPPs) [14] . DPPs can just readout the endogenous level of activated depalmitoylases in live cells, rather than specific targeting mitochondria. This kind of small molecule probe mostly depends on a shorter C8 lipid substrate, rather than a natural C16 lipid. So, the solubility of these probes in water is limited. Moreover, the portion of unnatural-based peptide in DPPs may not be substrates for some APTs, which results in false-positive signals. Subsequently, DPP5 is generated, which is featured by anionic carboxylate functional group to enhance probe water solubility [15] . Furthermore, such kind of DPPs could accommodate natural lipid substrate (C16) and improve APT selectivity. Thus, DPP5 represents an important tool to potentially avoid false-positive signals. Additionally, a recent study revealed that Wnt5a signaling pathway could regulate APT1 depalmitoylating activity through increasing its phosphorylation [16] . Therefore, it is possible that such fluorescent probe might be a reliable tool to uncover some new biological activities. Of note, even though APT1 is spatially localized in the mitochondria, either pharmacological perturbation or genetic knockdown of APT1 will suppress the function of APT1 throughout the cell. Furthermore, the depalmitoylation signal from mitoDPP-3 is completely blocked by Palmostatin B (PalmB) which inhibits all S-depalmitoylase activity, but selective inhibitor of APT1 or APT2 fails to do it. That's to say, there may be other depalmitoylases to be discovered. Thus, mitochondrial-specific regulatory functions of APT1 and subcellular-targeted inhibitors are required to uncover the cytosolic and mitochondrial roles of APTs. The general design of mitoDPPs makes it easy to expand researches in cysteine PTMs.
Intuitively, mitochondria, as primary drivers of metabolic regulation and source of long chain acyl-CoA, are easy to utilize S-palmitoylation as a main mechanism of dynamic protein lipidation. Therefore, S-palmitoylation is closely related to some metabolic diseases, since it is likely to induce lipid oxidation and tissue damage. Abnormal S-palmitoylation is found in tumor and neuronal diseases. Previous studies suggested the regulatory role of palmitoylation in ion channel proteins and identified its profound impacts on cardiac excitability [12] . However, further studies are needed to clarify whether S-palmitoylation plays a role in these metabolism and ion channelrelated diseases. If so, whether it can be a therapeutic target? Collectively, S-palmitoylation, as an important lipid post-translational mechanism, not only functions in regulating mitochondrial physiology, but also plays a vital role in some diseases such as neurodegenerative disorder, arrhythmia generation and tumorigenesis. Therefore, drugs to reverse aberrant palmitoylation are beneficial to maintain normal functions of mitochondria, which can prevent the development of some diseases.
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